Hikma Pharmaceuticals (HIK)
HIK Share PerformanceMore
|52 week high||2,703.0 02/08/16|
|52 week low||1,573.0 19/05/17|
|52 week change||-534.0 (-23.99%)|
|4 week volume||22,197,446 01/05/17|
Latest News« previous» nextMore
23/05/2017 - 11:00 StockMarketWire
JP Morgan Cazenove today reaffirms its neutral investment rating on Hikma Pharmaceuticals PLC (LON:HIK) and cut it...
23/05/2017 - 08:10 StockMarketWire
Cantor Fitzgerald today reaffirms its buy investment rating on Hikma Pharmaceuticals PLC (LON:HIK) and cut its price ...
22/05/2017 - 12:20 StockMarketWire
Numis today reaffirms its add investment rating on Hikma Pharmaceuticals PLC (LON:HIK) and set its price target at 20...
19/05/2017 - 16:59 StockMarketWire
Miners and utilities kept the FTSE in positive territory on a quiet day for corporate news. Anglo American (AAL) and Rio...
19/05/2017 - 14:44 RNS
RNS Number: 7108F Hikma Pharmaceuticals Plc 19 May 2017 Hikma Pharmaceuticals PLC Voting Results of 2017 Annual General Meeting LONDON, 19 May 2017 - Hikma Pharmaceuticals PLC (the " Company ") announces its Annual General Meeting (" AGM "), held at Sofitel St James, 6 Waterloo Place, London SW1Y 4AN on 19 May 2017 commenced at 10:00 am...
19/05/2017 - 13:57 Interactive Investor
This share is in freefall after delays to the approval process for one of its drugs. However, David Brenchley finds that anal...
19/05/2017 - 13:14 StockMarketWire
The FTSE gained momentum thanks to a rise in oil prices on hopes that output cuts would continue. Brent crude oil rallied...
19/05/2017 - 08:50 StockMarketWire
The FTSE embarked on a positive note as did its European counterparts, despite sterling vaulting higher on the dollar in w...
|Dividend yield||1.95 %|
Latest discussion posts More
“May elaborate on the reasons for FDA rejection despite HIk being very confident of approval & revenue flows from the second half of this year.”▼
“Looks like a basic schoolboy error. Or do the FDA have another ax to grind? Does not inspire confidence, they should have got this sorted out.”▼
“Nasty reaction to the FDA news; but I think it's overdone. Basically it means Hikma won't be earning any money from a product in a market where it has never earned any money. ...”▼
Codes & Symbols
|Symbols||HIK, LSE:HIK, HIK.L, HIK:LN, LON:HIK, XLON:HIK|